Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1941 + Nateglinide in Japanese T2DM
NCT01316107Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipragliflozin in type 2 diabetes mellitus (T2DM), sponsored by Astellas Pharma. Started Jan 2011; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01316107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01316107.